{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:48:14Z","timestamp":1743731294539,"version":"3.37.3"},"reference-count":29,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["HIV Research & Clinical Practice"],"published-print":{"date-parts":[[2021,3,4]]},"DOI":"10.1080\/25787489.2021.1915652","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T19:07:22Z","timestamp":1621278442000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Rapid initiation of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis"],"prefix":"10.1080","volume":"22","author":[{"given":"Keith","family":"Dunn","sequence":"first","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Rogers","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Bruce","family":"Simonson","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghan","family":"Luo","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubin","family":"Sheng","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purnima T.","family":"Kassam","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-8426","authenticated-orcid":false,"given":"Sareh","family":"Seyedkazemi","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Hardy","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. Updated 2019. Accessed January 12 2021."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.21579"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir699"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001196"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043754"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110039"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/35035103"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004543"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.21.11708-11717.2003"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw439"},{"key":"e_1_3_4_12_1","unstructured":"Prevention Access Campaign. Consensus statement. https:\/\/www.preventionaccess.org\/consensus. Issued 2016. Accessed January 12 2021."},{"key":"e_1_3_4_13_1","unstructured":"National Center for HIV\/AIDS Viral Hepatitis STD and TB Prevention Division of HIV\/AIDS Prevention. Evidence of HIV treatment and viral suppression in preventing the sexual transmission of HIV. https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/art\/cdc-hiv-art-viral-suppression.pdf. Published 2020. Accessed January 12 2021."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc.23447"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/428777"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1213"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2017.1387690"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001677"},{"key":"e_1_3_4_19_1","volume-title":"Treatment adherence and virologic response over 48 weeks among patients rapidly initiating darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in the DIAMOND study. Poster presented at: 14th International Conference on HIV Treatment and Prevention Adherence","author":"Hardy H","year":"2019","unstructured":"Hardy H, Luo D, Israel D, Simonson RB, Dunn K. Treatment adherence and virologic response over 48 weeks among patients rapidly initiating darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in the DIAMOND study. Poster presented at: 14th International Conference on HIV Treatment and Prevention Adherence; June 17\u201319, 2019; Miami, FL."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002015"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002357"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.1818"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002124"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0309"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy104"},{"key":"e_1_3_4_26_1","unstructured":"Centers for Disease Control and Prevention. Understanding the HIV care continuum. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/factsheets\/cdc-hiv-care-continuum.pdf. Published 2019. Accessed February 11 2021."},{"key":"e_1_3_4_27_1","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255884\/9789241550062-eng.pdf?sequence=1. Published 2017. Accessed December 22 2020."},{"key":"e_1_3_4_28_1","unstructured":"Dunn K Simonson RB Luo D et\u00a0al. High levels of patient satisfaction and virologic suppression at 48 weeks in newly diagnosed black\/African American individuals rapidly initiating darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in the DIAMOND study. Poster presented at: National Medical Association Annual Convention and Scientific Assembly; July 27\u201331 2019; Honolulu HI."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2020.1794439"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3080"}],"container-title":["HIV Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/25787489.2021.1915652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:00:52Z","timestamp":1717599652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/25787489.2021.1915652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,4]]}},"alternative-id":["10.1080\/25787489.2021.1915652"],"URL":"https:\/\/doi.org\/10.1080\/25787489.2021.1915652","relation":{},"ISSN":["2578-7489","2578-7470"],"issn-type":[{"type":"print","value":"2578-7489"},{"type":"electronic","value":"2578-7470"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhct21","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhct21","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}